

Improvement of Solubility and Dissolution by Lquisolid Compact

S.V Phoke^{*}, A.D Hatkar, S.S Jaybhaye

Department of Pharmaceutics, Institute of Pharmacy, Maharashtra, India

ABSTRACT

Liquisolid technique is a new technique for the drugs which has solubility problem. This technique proved to increase dissolution of poor water soluble drugs. In this technique liquid medications such as solutions or suspensions of water insoluble drugs in suitable non-volatile liquid vehicles can be changed into suitably flowing and compressible powders *via* blending with elected powder excipients. In these drug is held in solution around and excipient powder in surrounding, so drug is present in solubilized form, which increase dissolution.

Keywords: Lquisolid compacts; Liquid medication; low solubility drugs; Dissolution

INTRODUCTION

The solubility of a lot of active pharmaceutical ingredients is one of the technical challenges in formulating as suitable dosage form for efficient drug delivery. Most of the hydrophobic drugs termed as sparingly soluble, slightly soluble and very slightly soluble, undergo very poor dissolution in the gastro intestinal tract, leading to unpredictable and incomplete absorption. For these drugs, the dissolution process is the rate-controlling step, which determines the rate and degree of its absorption. Nearly 40%-50% of newly developed and orally administered drugs exhibit solubility problem in aqueous media due to its high lipophilicity, which directly reflects in the difficulty in formulation development of those drugs. Even though oral route is the most preferred route for drug administration due to its fulfilment of necessary strategies for drug development and patient acceptance, the poorly soluble drugs generally exhibit slow dissolution rates and incomplete bioavailability due to poor wettability in the Gastro Intestinal Tract (GIT) [1,2]. The drugs belonging to the Biopharmaceutical Classification System (BCS) class II and IV dissolve slowly, poorly or irregularly, which results in incomplete release of the drug from the dosage form, increase in the dose, large inter and intra-subject variation in blood drug concentrations under fed and fasted conditions ultimately leading to poor bioavailability. Over past few years, various formulation techniques have been developed, to improve the solubility and dissolution of poorly soluble substances, with different degrees of success. There are multiple methods which have been used for past many years, to enhance the dissolution

characteristics of water insoluble drugs which include micronization, lyophilization, solid dispersion etc [3-6]. Out of which the recent research focus on liquisolid compact technique as one of the successful tool to achieve the goal. Lquisolid compacts are acceptably flowing and compressible powder forms of liquid medications. The liquid medication is the water insoluble drugs carried in suitable non-volatile solvents. This liquid medication is converted into a free flowing powder by addition of suitable excipients. The concentrations of the carriers, coating materials, disintegrates, lubricants and glidants are optimized to get a non-sticky easily compressible blend. This technology ensures the promotion of dissolution rate of poorly water soluble drugs since the drugs are completely solubilized in the suitable solvents before converting it into free flowing mass [4,5]. The drug in the solid dosage form is held within the powder substrate in a solution or in a solubilized, almost molecular dispersion level, which is the main reason for its significant change in the wetting properties and effective surface area. The drug available for dissolution is increased and hence show enhanced drug release characteristics and improved oral bioavailability. The carrier and coating powder material can retain only certain amounts of liquid while maintaining acceptable flow and compression properties depending on the excipients ratio. The powder excipients ratio R is the fraction of weight of carrier (Q) and the coating material (q) present in the formulation $R=Q/q$. The maximum liquid load on the carrier material is termed as the liquid load factor.

Lf is defined as the weight ratio of the liquid medication (w) and carrier powder (Q) in the system $Lf=w/Q$, which must be

Correspondence to: SV Phoke, Department of Pharmaceutics, Institute of Pharmacy, Maharashtra, India, E-mail: sachinpharma08@gmail.com

Received: 4-Jan-2022, Manuscript No. JPCHS-22-46119; **Editor assigned:** 10-Jan-2022, PreQC No. JPCHS-22-46119(PQ); **Reviewed:** 24-Jan-2022, QC No. JPCHS-22-46119; **Revised:** 28-Jan-2022, Manuscript No. JPCHS-22-46119(R); **Published:** 04-Feb-2022, DOI:10/35248/2376-0419.2022.239

Citation: Phoke SV, Hatkar AD, Jaybhaye SS (2022) Improvement of Solubility and Dissolution by Lquisolid Compact. J Pharma Care Health Sys. 9:239.

Copyright: © 2022 Phoke S V, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

posed by an acceptable flowing and compressible preparation. The ϕ -value of a powder is the maximum amount of a given non-volatile liquid that can be held inside its bulk (w/w) while maintaining the reasonable flow. The ψ -number of a powder is the maximum amount of liquid that can be retained by a powder within its bulk (w/w) while maintaining acceptable compactability, so that while making cylindrical compacts with enough strength 'liquid-squeezing out' phenomena does not occur. The ϕ -value and the ψ -number of powder may be determined using the procedure Liquefied Flowability Test (LSF) and Liquefied Compressibility Test (LSC), respectively [6]. The compaction techniques can be proceeded *via* direct compression method and slugging method. The formulation of liquefied compacts has several merits which include simplicity; low cost and capability of industrial scale up production. Diazepam is a potent anti-epileptic and anti-anxiety drug with narrow therapeutic index. Its poor solubility in water slows down the dissolution, leading to restricted absorption. The present work emphasis on the development of liquefied compact formulation for this deserving drug candidate to enhance its solubility and dissolution, thereby increase its absorption in the GIT [6]. The dissolution properties of a drug and its release from a dosage form have a basic impact on its bioavailability. Solving solubility problems is a major challenge for the pharmaceutical industry with developments of new pharmaceutical products, since nearly half of the active substances being identified through the new paradigm in high throughput screening are either insoluble or poorly soluble in water. The rate of dissolution of a drug is a function of its intrinsic solubility and its particle size. Studies with poorly soluble drugs have demonstrated that particle size reduction to the sub-micron range can lead to an increase in dissolution rate and higher bioavailability.

Poorly water soluble drugs belong to BCS class II and class IV group of compounds. In the process of absorption of drug from oral route; dissolution is the rate limiting step for lipophilic drugs; therefore it is necessary to enhance dissolution of these drugs to ensure maximum therapeutic utility of these drugs [7]. Dissolution is a process by which a solid substance goes into solution. The extents to which the dissolution proceeds, under a given set of conditions are referred to as the solubility of the substance in the solvent i.e. rate of solution (dissolution) and amount that can be dissolved (solubility) are not same. The dissolution rate of a drug is directly proportional to its solubility as per Noyes-Whitney equation and therefore solubility of a drug substance is a major factor that determines its dissolution rate and hence its absorption and bioavailability eventually. The various properties of drug that affect drug dissolution and its rate includes solubility, particle size, polymorphism, salt form, complexation, wettability and can be targeted to enhance dissolution of poorly water soluble drugs [8]. Micronization is the most common method to increase the drug surface area. But, in practice, the effect of micronization is often disappointing, especially when the drugs are encapsulated or tableted. The most promising method for promoting dissolution is the formation of liquefied tablets. Formulating liquid medications into solid compacts has been the object of many studies. On producing solid solutions and liquefieds based on the concept

of blending liquid medications with selected powder excipients to produce free flowing, readily compressible powders [9].

A liquefied system refers to formulations formed by conversion of liquid drugs, drug suspensions or drug solution in non-volatile solvents, into dry, non-adherent, free-flowing and compressible powder mixtures by blending the suspension or solution with selected carriers and coating materials. Various grades of cellulose, starch lactose, sorbitol may be used as the carrier; whereas very fine particle size silica powder may be used as the coating material [10,11]. Sustained release dosage form is mainly designed for maintaining therapeutic blood or tissue levels of the drug for extended period of time with minimized local or systemic adverse effects. Economy and greater patient compliance are other advantages. In recent years, clinical studies on Tramadol Hydrochloride have demonstrated that this drug is an effective agent for moderate to severe chronic pain. The half-life of the drug is about 5.5 hours and the usual oral dosage regimen is 50 to 100 mg every 4 to 6 hours with a maximum dosage of 400 mg/day. To reduce frequent administration of dosage form and to improve patient compliance, a sustained-release formulation tramadol is desirable. The drug is freely water soluble and hence judicious selection of release retarding excipients is necessary to achieve a constant *in vivo* input rate of the drug. Various approaches have been used by researchers to sustain drug release in the form of tablets [12,13].

LITERATURE REVIEW

Liquefied system is novel technique developed by Spireas [14-16]. "Liquefied systems" involves conversion of liquid lipophilic drugs or water insoluble solid drugs dissolved in non-volatile solvent and this liquid medication can be converted into free-flowing, non-adherent, dry looking, and readily compressible powders with use of carrier and coating materials. In case of water soluble drugs, the sustained release can be obtained. The term liquefied compacts as described as [15,16] indicates that immediate or sustained release tablets or capsules that are prepared using the technique of "liquefied systems" combined with inclusion of appropriate adjuvants required for tableting or encapsulation such as lubricants and for rapid or sustained release action, such as disintegrates or binders, respectively. Low cost, simple formulation technique and capability of industrial production serve to be advantages of this technique. Historically, liquefied compacts are descendants of 'powdered solutions', an older technique which was based on the conversion of a solution of a drug in a non-volatile solvent into a dry-looking, non-adherent powder by mainly adsorbing the liquid onto silica's of large specific surfaces. Such preparations, however, have been investigated for their dissolution profiles while being in a powder dispersion form and not as compressed entities, simply because they could not be compressed into tablets. In later studies on powdered solutions, compression enhancers such as microcrystalline cellulose were added in such dispersions in order to increase the compressibility of the systems. In these studies, however, large quantities of silica's were still being used, and the flow and compression properties of the products were never validated and standardized to industrial specifications and requirements. Specifically, when

such modified powdered solutions were compressed into tablets, they presented significant 'liquid squeezing out' phenomena and unacceptably soft tablets, thereby hampering the industrial application of such systems.

Liquisolid compacts, on the other hand, are acceptably flowing and compressible powdered forms of liquid medications, and have industrial application. In addition, the term 'liquid medication' does not only imply drug solutions, as in powdered solutions, but also drug suspensions, emulsions, or liquid oily drugs. Therefore, in contrast to 'powdered solutions', the term 'liquisolid compacts' is more general and it may encompass four different formulation systems namely,

1. Powdered drug solutions
2. Powdered drug suspensions
3. Powdered drug emulsions
4. Powdered liquid drugs

Furthermore, the earlier term 'powdered solutions' seems to be inadequate even in describing the original systems, since it has not been proven that the drug remains in solution in the liquid vehicle after its deposition on the extremely large powder surfaces of silica's used.

Advantages of liquisolid compact

- A great number of slightly and very slightly water-soluble and practically water-insoluble liquid and solid drugs such as digitoxin, prednisolone and hydrocortisone etc. can be formulated into liquisolid systems using the new formulation-mathematical model.
- Better availability of an orally administered water-insoluble drug is achieved when the drug is in solution form.
- Though the drug is in a tableted or encapsulated dosage form it is held in a solubilized liquid state, which consequently contributes to increased drug wetting properties, thereby enhancing drug dissolution.
- Production cost of liquisolid systems is lower than that of soft gelatin capsules.
- Advantage of liquisolid systems, particularly for powdered liquid drugs, during dissolution of a liquisolid tablet, after the disintegration process is completed, the drug solution or liquid drug, carried on the suspended and thoroughly agitated primary particles, is dispersed throughout the volume of the dissolution medium; such a phenomenon does not extensively occur during the dissolution process of soft gelatin capsule preparations. Therefore, since more drug surface is exposed to the dissolving medium, liquisolid systems exhibit enhanced drug release.
- Optimized rapid-release liquisolid tablets or capsules of water-insoluble drugs exhibit enhanced *in vitro* and drug release as compared to their commercial counterparts.
- Optimized sustained-release liquisolid tablets or capsules of water-insoluble drugs exhibit surprisingly constant dissolution rates (zero-order-release) comparable only to expensive commercial preparations that combine osmotic pump technology and laser-drilled tablets [10].

Disadvantages of liquisolid system

- The liquisolid systems have low drug loading capacities and they require high solubility of drug in non-volatile liquid vehicles.
- It requires more efficient excipients which have higher adsorption capacities which provide faster drug release with a smaller tablet size to improve liquisolid formulations.
- To maintain acceptable flowability and compatibility for liquisolid powder formulation high levels of carrier and coating materials are require and that in turn will increases the weight of each tablet above 1gm which is very difficult to swallow.

Need of liquisolid system

The oral route remains the preferred route of drug administration due to its convenience, good patient compliance and low medicine production costs. In order for a drug to be absorbed into the systemic circulation following oral administration, the drug must be dissolved in the gastric fluids. Thus, one of the major challenges to drug development today is poor solubility, as an estimated 40% of all newly developed drugs are poorly soluble or insoluble in water. In addition, up to 50% of orally administered drug compounds suffer from formulation problems related to their low solubility and high lipophilicity. Bioavailability of poorly water soluble hydrophobic drugs (class II in bio pharmaceuticals classification system) is limited by their solubility and dissolution rate. The dissolution rate of these drugs can be improved by decreasing particle size, decreasing crystallinity, and or increasing the surface area. Several studies have been carried out to increase the dissolution rate of drugs by decreasing the particle size, by creating nanoparticles and micro particles. However, the fine drug particles have high tendency to agglomerate due to van der Waals attraction or hydrophobicity, which both result in a decrease in surface area over time. Another way of increasing the dissolution rate is adsorption of the drug onto a high-surface area carrier. In this technique, the drug is dissolved in an organic solvent followed by soaking of the solution by a high-surface-area carrier such as silica. Here, agglomeration of the drug particles is prevented due to the binding of drug to the carrier. However, due to the presence of the residual solvent in the drug formulation, it is disadvantageous to use toxic solvents [11-13]. To overcome the problem, the technique of 'liquisolid compacts' is a new and promising approach towards dissolution enhancement. Liquisolid compacts possess acceptable flowability and compressibility properties. They are prepared by simple blending with selected powder excipients referred to as the carriers and the coating materials. Many grades of cellulose, starch, lactose, etc. can be used as carriers, whereas silica's of very fine particle size can be used as coating materials. In such systems, the drug existed in a molecular state of subdivision and systems were free flowing, on-adherent, dry looking powders. This technique was successfully applied for low dose water-insoluble drugs. Due to significantly increased wetting properties and surface area of drug available for dissolution, liquisolid compacts of water insoluble substances may be expected to display enhanced drug release characteristics and, consequently, improved oral bioavailability. Since dissolution of

a non-polar drug is often the rate limiting step in gastrointestinal absorption, better bioavailability of an orally administered water-insoluble drug is achieved when the drug is already in solution, thereby displaying enhanced dissolution rates. The technique of liquisolid compacts has been successfully employed to improve the *in vitro* release of poorly water soluble drugs such as carbamazepine, famotidine, piroxicam, indomethacin, hydrocortisone, naproxen and prednisolone [13].

CONCEPT

When the drug dissolved in the liquid vehicle is incorporated into a carrier material which has a porous surface and closely matted fibers in its interior as cellulose, both absorption and adsorption take place; i.e. the liquid initially absorbed in the interior of the particles is captured by its internal structure, and after the saturation of this process, adsorption of the liquid onto the internal and external surfaces of the porous carrier particles occur. Then, the coating material having high adsorptive properties and large specific surface area gives the liquisolid system the desirable flow characteristics (Figure 1).




Figure 1: Steps in liquisolid.

The wettability of the compacts by the dissolution media is one of the proposed mechanisms for explaining the enhanced dissolution rate from the liquisolid compacts. Non-volatile solvent present in the liquisolid system facilitates wetting of drug particles by decreasing interfacial tension between dissolution medium and tablet surface.

Components of liquisolid compact

Liquisolid compact mainly includes

- Nonvolatile solvent
- Disintegrates
- Drug candidate
- Carrier material
- Coating material

Nonvolatile solvent: Nonvolatile Solvent should be Inert, high boiling point, preferably water-miscible and not highly viscous organic solvent systems and compatible with having ability to solubilize the drug [17]. The nonvolatile solvent acts as a binding agent in the liquisolid formulation. Various non-volatile solvents used for the formulation of liquisolid systems include Polyethylene glycol 200 and 400, glycerin, polysorbate 80 and propylene glycol.

Disintegrates: Superdisintegrants increases the rate of drug release, water solubility and wettability of liquisolid granules.

Mostly superdisintegrants like sodium starch glycolate and crosspovidone are used [18].

Drug candidates: This technique was successfully applied for low dose BCS class II and class IV drugs which are poorly water soluble and have slow dissolution rate. Examples of drug candidates include carbamazepine, famotidine, piroxicam, indomethacin, hydrocortisone, naproxen and prednisolone, digitoxin, Hydrocortisone, spironolactone, hydrochlorothiazide, polythiazide, and other liquid medications such as chlorpheniramine, water insoluble vitamins, fish oil etc [18].

Carrier materials: Carrier material should be porous material possessing enough absorption properties which contributes in liquid absorption. The carrier and coating materials can retain only certain amounts of liquid and at the same time maintain acceptable flow and compression properties hence, increasing moisture content of carrier's results in decreased powder flowability. These include grades of microcrystalline cellulose such as avicelPH102 and avicelPH200, lactose, eudragit RI and eudragitRS12 (to sustain drug delivery) etc.

Coating materials: Coating material should be a material possessing fine and highly adsorptive particles which contributes in covering the wet carrier particles and displaying a dry-looking powder by adsorbing any excess liquid. Coating material is required to cover the surface and so maintain the powder flowability. Coating material includes silica (Cab-O-Sil) M5, aerosil 200, syloid, 244FP etc.


Formulation of liquisolid compact

The formulation part of liquisolid compact mainly includes Pre-formulation studies and formulation of liquisolid compact system.

- Determination solubility of drug in different non-volatile solvents.
- Determination of angle of slide
- Determination of flowable liquid retention potential (Φ value)
- Calculation of Liquid Load Factor (LF)
- Liquisolid Compressibility Test (LSC)

Solubility studies: Solubility studies are carried out by preparing saturated solutions of drug in non-volatile solvent and analyzing them spectrophotometrically. Saturated solutions are prepared by adding excess of drug to non-volatile solvent and shaking them on shaker for specific time period under constant vibration. After this, the solutions are filtered and analyzed spectrophotometrically.

Determination of angle of slide: Angle of slide is used as a measure of the flow properties of powders. Determination of angle of slide is done by weighing the required amount of carrier material and placed at one end of a metal plate with a polished surface. The end is gradually raised till the plate becomes angular to the horizontal at which powder is about to slide. This angle is known as angle of slide. Angle of 33° is regarded as optimum (Figure 2).



Determination of flowable liquid retention: The term "flowable liquid-retention potential" (Φ -value) of a powder material describes its ability to retain a specific amount of liquid while maintaining good flow properties. The Φ -value is defined as the maximum weight of liquid that can be retained per unit weight of the powder material in order to produce an acceptably flowing liquid/powder admixture. The Φ values are calculated according to equation,

$$\Phi \text{ value} = \text{weight of liquid} / \text{weight of solid} \dots (1)$$

Calculation of liquid Load Factor (LF): Different concentrations of non-volatile solvents are taken and the drug is dissolved. Such liquid medication is added to the carrier coating material admixture and blended. Using equation 2 drug loading factors are determined and used for calculating the amounts of carrier and coating materials in each formulation.


$$Lf = \text{weight of liquid medication} / \text{weight of carrier material} \dots (2)$$

Liquisolid Compressibility Test (LSC): Liquisolid compressibility test is used to determine Φ values and involves steps such as preparing carrier coating material admixture systems, preparing several uniform liquid or powder admixtures, compressing each liquid or powder admixtures to tablets, assessing average hardness, determination of average liquid content of crushed tablets, as well as determining plasticity, sponge index and Φ value and Lf.

Preparation of liquisolid tablets

- A drug substance was initially dispersed in the non-volatile solvent systems (polysorbate 80, polyethyleneglycol-200) termed as liquid vehicles with different drug: vehicle ratio.
- Then a mixture of carrier or different polymers and excipients were added to the above liquid medication under continuous mixing in a mortar. These amounts of the carrier and excipients are enough to maintain acceptable flow and compression properties.
- To the above binary mixture disintegrates like sodium starch glycolate and other remaining additives were added according to their application and mixed for a period of 10 to 20 min in a mortar.
- The final mixture was compressed using the manual tableting machine to achieve tablet hardness.

- Characterize the final liquisolid granules for solubility, dissolution, flowability, compressibility and other physicochemical properties (Figure 3).



DISCUSSION

Flow properties are the important concern in the formulation and industrial production of tablet dosage form. Angle of repose is characteristic to the flow rate of powder. In general, values of angle of repose $\geq 40^\circ$ indicate powders with poor flowability. It is necessary to determine any possible interaction between excipients used in the formulation. This will also indicate success of stability studies. If the characteristic peak for the drug is absent in the DSC thermogram, there is an indication that the drug is in the form of solution in liquisolid formulation and hence it is molecularly dispersed within the system. Generally, disappearance of characteristic peaks of drug in the liquisolid formulation and retaining peaks of carrier material is observed. This indicates that drug gets converted to amorphous form or in solubilized form in the liquisolid formulation. After SEM study, complete disappearance of crystals of drug which confirms that drug is totally solubilized in liquisolid system and this ensures the complete solubility. After complete formulation, Tablets are evaluated by carrying out tests for weight variation, uniformity of tablet thickness and diameter, humidity content using Karl fisher method, friability, hardness, disintegration, dissolution, and content uniformity. All these tests are carried out in triplicate and according to the compendial specifications. For content uniformity test tablets should contain not less than 95% and not more than 105% of the labelled potency. The disintegration test was carried out on six tablets in distilled water at $37^\circ\text{C} \pm 32^\circ\text{C}$ using the USP disintegration apparatus.

CONCLUSION

Many researchers revealed that at low drug concentrations in liquid medication, more rapid release rates are observed. The consistent and higher dissolution rate displayed by liquisolid compacts will improve the absorption of drug from gastrointestinal tract. Generally Dissolution studies of Liquisolid tablet are carried out using dissolution apparatus USP II at $37^\circ\text{C} \pm 32^\circ\text{C}$. The improvement in oral bioavailability was confirmed by estimating the pharmacokinetic parameters in various animals such as rabbit beagle dog. Results show that absolute bioavailability of drug from liquisolid tablets was much higher than marketed tablets.

REFERENCES

1. Yadav VB, Yadav AV. Improvement of solubility and dissolution of indomethacin by liquisolid and compaction granulation technique. *J Pharm Sci.* 2009;1(3):44.[Cross Ref], [Google scholar]
2. Nokhodchi A, Javadzadeh Y, Siahi-Shadbad MR, Barzegar-Jalali M. The effect of type and concentration of vehicles on the dissolution rate of a poorly soluble drug indomethacin from liquisolid compacts. *J Pharm Pharm Sci.* 2005;8(1):18-25.[Cross Ref], [Google scholar]
3. Spireas SS, Jarowski CI, Rohera BD. Powdered solution technology: principles and mechanism. *Pharm Res.* 1992;9(10):1351-8. [Cross Ref], [Google scholar]
4. Patravale VB, Date AA, Kulkarni RM. Nanosuspensions: a promising drug delivery strategy. *J Pharm Pharmacol.* 2004;56(7):827-40. [Cross Ref], [Google scholar]
5. Kesisoglou F, Panmai S, Wu Y. Nanosizing oral formulation development and biopharmaceutical evaluation. *Adv Drug Deliv Rev.* 2007;59(7):631-44. [Cross Ref], [Google scholar]
6. Spireas S, Sadu S. Enhancement of prednisolone dissolution properties using liquisolid compacts. *Int J Pharm.* 1998;166(2):177-88. [Cross Ref], [Google scholar]
7. Spireas S, Wang T, Grover R. Effect of powder substrate on the dissolution properties of methyclothiazide liquisolid compacts. *Drug Dev Ind Pharm.* 1999;25(2):163-8.[Cross Ref], [Google scholar]
8. Bhavya E, Dhere MD. Liquisolid compacts technique of poor water soluble drugs: An overview. *Res J Pharm Technol.* 2021;14(10):5569-72.[Cross Ref], [Google scholar]
9. Javadzadeh Y, Jafari-Navimipour B, Nokhodchi A. Liquisolid technique for dissolution rate enhancement of a high dose water-insoluble drug (carbamazepine). *Int J Pharm.* 2007;341(1-2):26-34. [Cross Ref], [Google scholar]
10. Nokhodchi A, Javadzadeh Y, Siahi-Shadbad MR, Barzegar-Jalali M. The effect of type and concentration of vehicles on the dissolution rate of a poorly soluble drug (indomethacin) from liquisolid compacts. *J Pharm Pharm Sci.* 2005;8(1):18-25.[Cross Ref], [Google scholar]
11. Fahmy RH, Kassem MA. Enhancement of famotidine dissolution rate through liquisolid tablets formulation: *in vitro* and *in vivo* evaluation. *Eur J Pharm Biopharm.* 2008;69(3):993-1003.[Cross Ref], [Google scholar]
12. Naseem A, Olliff CJ, Martini LG, Lloyd AW. Effects of plasma irradiation on the wettability and dissolution of compacts of griseofulvin. *Int J Pharm.* 2004;269(2):443-50. [Cross Ref], [Google scholar]
13. Gursoy RN, Benita S. Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs. *Biomed Pharmacother.* 2004;58(3):173-82.[Cross Ref], [Google scholar]
14. Yadav VB, Yadav AV. Solvent Diffusion (ESD) Technique. *Int J Pharma Bio Sci.* 2010;1:1.[Cross Ref], [Google scholar]
15. Javadzadeh Y, Musaalrezaei L, Nokhodchi A. Liquisolid technique as a new approach to sustain propranolol hydrochloride release from tablet matrices. *Int J Pharm* 2008;362:102-8.[Cross Ref], [Google scholar]
16. Tayel SA, Soliman II, Louis D. Improvement of dissolution properties of carbamazepine through application of the liquisolid tablet technique. *Eur J Pharm Biopharm.* 2008;69(1):342-7.[Cross Ref], [Google scholar]
17. Yadav VB, Yadav AV. Liquisolid granulation technique for tablet manufacturing: an overview. *J Pharm Res.* 2009;2(4):670-4. [Cross Ref], [Google scholar]
18. Rokade M, Khandagale P, Phadtare DI. Liquisolid compact techniques: a review. *Int J Curr Pharm Res.* 2018;10(4):1-5. [Cross Ref], [Google scholar]